{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hepatitis+C+Virus+Genotype-1&page=3", "query": { "condition": "Hepatitis C Virus Genotype-1", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 206, "total_pages": 21, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hepatitis+C+Virus+Genotype-1&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hepatitis+C+Virus+Genotype-1&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-10T05:28:00.965Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01821963", "title": "Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Infection" ], "interventions": [ { "name": "Pegylated Interferon Alfa 2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "Telaprevir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "69 Years", "sex": "ALL", "summary": "18 Years to 69 Years" }, "enrollment_count": 1, "start_date": "2013-04", "completion_date": "2014-02", "has_results": true, "last_update_posted_date": "2020-09-24", "last_synced_at": "2026-10-10T05:28:00.965Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01821963" }, { "nct_id": "NCT02347345", "title": "Immunologic Effects of HCV Therapy With HARVONI in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Harvoni (Fixed dose combination ledipasvir/sofosbuvir)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rockefeller University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 34, "start_date": "2016-11-15", "completion_date": "2016-11-15", "has_results": true, "last_update_posted_date": "2019-08-13", "last_synced_at": "2026-10-10T05:28:00.965Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02347345" }, { "nct_id": "NCT02073656", "title": "Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C Virus", "HIV" ], "interventions": [ { "name": "LDV/SOF", "type": "DRUG" }, { "name": "RBV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 335, "start_date": "2014-02", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2018-11-16", "last_synced_at": "2026-10-10T05:28:00.965Z", "location_count": 34, "location_summary": "Birmingham, Alabama • Los Angeles, California • Newport Beach, California + 31 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02073656" }, { "nct_id": "NCT02226549", "title": "Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection and Cirrhosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C Virus Infection" ], "interventions": [ { "name": "LDV/SOF", "type": "DRUG" }, { "name": "VDV", "type": "DRUG" }, { "name": "RBV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2014-07", "completion_date": "2015-02", "has_results": true, "last_update_posted_date": "2018-11-16", "last_synced_at": "2026-10-10T05:28:00.965Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02226549" }, { "nct_id": "NCT01471574", "title": "Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C, Genotype 1" ], "interventions": [ { "name": "Daclatasvir", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "PEG-Interferon alfa 2a", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 549, "start_date": "2011-12", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2016-01-29", "last_synced_at": "2026-10-10T05:28:00.965Z", "location_count": 23, "location_summary": "Birmingham, Alabama • La Jolla, California • Los Angeles, California + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01471574" }, { "nct_id": "NCT01563536", "title": "Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis C Infection" ], "interventions": [ { "name": "ABT-267", "type": "DRUG" }, { "name": "ABT-450", "type": "DRUG" }, { "name": "ABT-333", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie (prior sponsor, Abbott)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 12, "start_date": "2012-02", "completion_date": "2013-06", "has_results": true, "last_update_posted_date": "2018-07-02", "last_synced_at": "2026-10-10T05:28:00.965Z", "location_count": 4, "location_summary": "Bakersfield, California • Orlando, Florida • Annapolis, Maryland + 1 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Annapolis", "state": "Maryland" }, { "city": "Poughkeepsie", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01563536" }, { "nct_id": "NCT02315638", "title": "Long-Term Follow-Up Safety Monitoring of Patients Dosed in the First-in-Man Phase I/II Study of TT-034.", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hepatitis C" ], "interventions": [], "intervention_types": [], "sponsor": "Tacere Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2014-11", "completion_date": "2018-09-24", "has_results": false, "last_update_posted_date": "2018-09-26", "last_synced_at": "2026-10-10T05:28:00.965Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02315638" }, { "nct_id": "NCT00963885", "title": "A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "Copegus", "type": "DRUG" }, { "name": "Pegasys", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "RO5190591 (Danoprevir)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 229, "start_date": "2009-08", "completion_date": "2012-01", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-10-10T05:28:00.965Z", "location_count": 24, "location_summary": "Phoenix, Arizona • Long Beach, California • Los Angeles, California + 20 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00963885" }, { "nct_id": "NCT01331850", "title": "A Study of Danoprevir/Ritonavir and Copegus With RO5024048 and/or Pegasys in Patients With Chronic Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "Copegus", "type": "DRUG" }, { "name": "Pegasys", "type": "DRUG" }, { "name": "RO5024048", "type": "DRUG" }, { "name": "danoprevir", "type": "DRUG" }, { "name": "ritonavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 381, "start_date": "2011-05", "completion_date": "2013-01", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-10-10T05:28:00.965Z", "location_count": 19, "location_summary": "La Jolla, California • Long Beach, California • Sacramento, California + 15 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01331850" }, { "nct_id": "NCT02167945", "title": "A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Hepatitis C Virus (HCV) Infection Genotype 1" ], "interventions": [ { "name": "ABT-450/r/ABT-267", "type": "DRUG" }, { "name": "ABT-333", "type": "DRUG" }, { "name": "Ribavirin (RBV)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 615, "start_date": "2014-06-12", "completion_date": "2021-05-13", "has_results": true, "last_update_posted_date": "2022-07-19", "last_synced_at": "2026-10-10T05:28:00.965Z", "location_count": 48, "location_summary": "Phoenix, Arizona • Bakersfield, California • Los Angeles, California + 40 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02167945" } ] }